UPB
Upstream Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.34
+0.56%Sep 8, 2026, 07:30 UTC
Upstream Bio presented results from the Phase 2 VALIANT trial of verekitug for severe asthma at the ERS Congress 2026 in Barcelona, showing a 56% reduction in AAER versus placebo and improved lung function and FeNO.
Source:Sep 1, 2026, 11:00 UTC
Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and CRSwNP, with trials to start in Q1 2027.
Source:Aug 11, 2026, 13:36 UTC
Upstream Bio, Inc. reported a second-quarter net loss of $0.73 per share, narrower than the Zacks Consensus Estimate of a $0.78 loss and slightly improved from a $0.74 loss a year earlier.
Source: